Table 3.
Hazard ratio for major adverse cardiovascular events* comparing clopidogrel use with non-use, with and without concomitant use of statins
| Clopidogrel use | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number† | Rates† | ||||||||||
| − | + | − | + | Unadjusted hazard ratio (95% CI) | Interaction effect‡ (95% CI) | P§ | Adjusted hazard ratio¶ (95% CI) | Interaction effect‡ (95% CI) | P§ | ||
| Overall†† | − | 838 | 231 | 446 | 130 | 0.32 (0.28, 0.38) | 0.34 (0.29, 0.40) | ||||
| + | 237 | 584 | 108 | 104 | 0.66 (0.56, 0.77) | 2.03 (1.64, 2.51) | <0.0001 | 0.68 (0.58, 0.79) | 1.97 (1.59, 2.44) | <0.0001 | |
| Simvastatin | − | 881 | 292 | 395 | 130 | 0.35 (0.30, 0.40) | 0.34 (0.30, 0.39) | ||||
| + | 194 | 523 | 105 | 101 | 0.65 (0.55, 0.78) | 1.87 (1.51, 2.32) | <0.0001 | 0.66 (0.56, 0.79) | 1.95 (1.57, 2.41) | <0.0001 | |
| Atorvastatin | − | 1031 | 755 | 277 | 109 | 0.38 (0.34, 0.42) | 0.38 (0.34, 0.43) | ||||
| + | 44 | 60 | 124 | 126 | 0.64 (0.43, 0.95) | 1.68 (1.13, 2.51) | 0.0110 | 0.63 (0.43, 0.93) | 1.65 (1.10, 2.46) | 0.01 | |
Composite of myocardial infarction, ischaemic stroke, stent thrombosis, target lesion revascularization and cardiac death.
Numbers reflect exposure status at time of outcome. Rates are number of events per 1000 person years.
The ratio of the stratum-specific hazard ratios, which estimates the relative hazard rate increase associated with concomitant use of clopidogrel and statins, beyond that expected from the independent effects of these drugs alone.
Wald χ2 test for no interaction in the model.
Adjusted for age, gender, diabetes, hypertension, obesity and time-varying use of aspirin, calcium channel blockers and proton pump inhibitors.
Current use of simvastatin, lovastatin or atorvastatin.